{"name":"Ophthalmic Consultants of Boston","slug":"ophthalmic-consultants-of-boston","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Intravitreal Aflibercept Injection","genericName":"Intravitreal Aflibercept Injection","slug":"intravitreal-aflibercept-injection","indication":"Neovascular (wet) age-related macular degeneration","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Moxifloxacin ophthalmic solution 0.5%","genericName":"Moxifloxacin ophthalmic solution 0.5%","slug":"moxifloxacin-ophthalmic-solution-0-5","indication":"Bacterial conjunctivitis","status":"marketed"}]}],"pipeline":[{"name":"Intravitreal Aflibercept Injection","genericName":"Intravitreal Aflibercept Injection","slug":"intravitreal-aflibercept-injection","phase":"marketed","mechanism":"Aflibercept is a soluble decoy receptor that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with endogenous receptors and reducing abnormal blood vessel growth in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema","Diabetic retinopathy"],"catalyst":""},{"name":"Moxifloxacin ophthalmic solution 0.5%","genericName":"Moxifloxacin ophthalmic solution 0.5%","slug":"moxifloxacin-ophthalmic-solution-0-5","phase":"marketed","mechanism":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.","indications":["Bacterial conjunctivitis","Bacterial keratitis","Bacterial corneal ulcer","Prophylaxis of bacterial infection following ocular surgery"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vQUExMERQMElsRkhiNTVxSE1yWDc0aWFmM0tKQ0Z3eEVEVEJNUnhjdEdDNk9rUjJhSkxUMnFGUlFaM0d6ZUdubERxWkFYLUZjWm9VaWtvR1NMVHctR0NZ?oc=5","date":"2025-01-13","type":"trial","source":"nature.com","summary":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration: week 48 results from the phase 3 PULSAR trial | Eye - nature.","headline":"Infographic: Efficacy and safety of high-dose Intravitreal aflibercept 8 mg in patients with neovascular age-related mac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOLU1wMXJfNGpZYnZNaUFKaDYwRFlfVHZJNDExMWFzSWFvaTB3WHVvN2tnSFA1VUFIcXJoM2YzN2o4QUlmNDhONVl5c2JMeGh3RFUyRFJiWHdhYWswbG85SXBVUFAxTFloTnVTdThrUklZblZ4LUx0M0hwUnNwZ1hFcGcxbUFuWm14M3F0amdzRG5YckJHXzFlRDVWbTkyTnlNYWRUcTBWbjM2VjlXbW5PazRwNl82WE1YNzZ5T3pnMA?oc=5","date":"2024-09-19","type":"trial","source":"Modern Retina","summary":"Alkeus Pharmaceuticals shares results of SAGA study of oral gildeuretinol acetate for GA - Modern Retina","headline":"Alkeus Pharmaceuticals shares results of SAGA study of oral gildeuretinol acetate for GA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB0RXRadEdJcjBERi1SLXd4bnVEWkpHc2ZpYllaT3pUSTBvVmVzeENleHVaczV6Vkd3cnVqdlV4eDhkRVVOQUw2ZE5HREtqWEVvd3FJTzRiZzNlQnZJclFZ?oc=5","date":"2024-04-15","type":"pipeline","source":"nature.com","summary":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy - nature.com","headline":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOOHRPRms2Q2JSdm80Y01LSld3LVBaOVNtdXJrUDB3M3haZlZFTFFIYk0wZUFfOEM4UmNUYkttQ0czTG9wTXdUUDhwcnhLVnR6Qjh2aldkS2pwOHJyRmlFTXloUEtJci1PZUhueGpzb0w2c0pYRU02UVp2am00RnJwNEVoZmNFcnBkY1pISWp0UkNpUzJXdjJ5R2twbw?oc=5","date":"2023-11-04","type":"trial","source":"Ophthalmology Times","summary":"AAO 2023: Apellis unveils data from GALE extension study - Ophthalmology Times","headline":"AAO 2023: Apellis unveils data from GALE extension study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOUZDRlRYSWJSVmZTbXRIWmd2WFlVMldnWm41RW8yNUkxdklWWHVIeXFNV29BRkdZUmRTU0l4MjlIQjhUYml6bjZqRGhzR0JOVlBNdGdlZ2d1Q2NXbjZUMzFzaEFtX1Z6dWx2V3pIMHlMYU5uOThOWmVpazhGeEZEZ2UxTkF0anZJUllpYXFMdXVYZU1PSW1mOEZZNFRFcXJlMGpNNUhUTHNKSlFJTnYzODBWRkFnUHFYd1hz?oc=5","date":"2023-03-29","type":"pipeline","source":"The Boston Globe","summary":"Waltham biotech’s vision loss drug helps slow a form of macular degeneration - The Boston Globe","headline":"Waltham biotech’s vision loss drug helps slow a form of macular degeneration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTG5HZlRiR2J6d3lSd2w0MkYxRDl3aGdtZWZHVTdlUkNKZ1B0dzlQVE1scUhQblZad3MzUmhBWVNObHNnOW5GVEd0UmdaQno1TnloeDU1eVFpS1FrelRScmVteExqWFFMd0xxTE5feFVaSG9udDVkZGZwWVo5clVYMFJLaFYzcTFCTEt2QTBOaDE4aHYyTVRMUmw2RFkwSDN3dS02eWpFZ0NfVlAzQS16dGE2VFg5Z0ZjSmYw?oc=5","date":"2021-07-06","type":"trial","source":"Fierce Biotech","summary":"Unity, on the rebound after catastrophe, shows promising results in early eye disease trial - Fierce Biotech","headline":"Unity, on the rebound after catastrophe, shows promising results in early eye disease trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNakhWREFrb0ZjeUxobTRBVGNUOE9EeHRjOEsyLUNHaHh0TC1iNnBxcXNhWXBkYThjRE82ajBSMFZlbkw2ZUZRc2Yzclg5VDN6VDUza1hyVHZvRlZvaEVMdmVTeGRnV0U0ZktHNlFodnplYzNrUkpWekEzaWhyY2RoTl9tbnF2X0Z5cXhCenhPNzEzSGQ1cXEwWDRhV3RLdw?oc=5","date":"2021-02-12","type":"regulatory","source":"Fierce Biotech","summary":"Roche's Eylea rival poised for FDA filings with new phase 3 data - Fierce Biotech","headline":"Roche's Eylea rival poised for FDA filings with new phase 3 data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPM3dNMWg2cUlvR29qWDBVRUliNkQzVTV0dy1ydVozblIwNktmQUJnYlBWbVNjWDA4WHlRWFJobWRYOGtrUWVseE1CSEVMNHB4YTFHT0VoMGtOQ0NUNXQxbHdmdktoUDN3ZkRKdVNOSVBfUDdOWS1sUTRCRndqVmYtRER5UFUzVlVGZm5CT1ZQV0w1UXk5TXo5RFBlN1lPTXZ1UUNMenY5QWptcm5LUFFuRldJZ3g5RjQtMWln?oc=5","date":"2020-03-30","type":"pipeline","source":"PR Newswire","summary":"Eyevance Pharmaceuticals Launches ZERVIATE™ in the United States - PR Newswire","headline":"Eyevance Pharmaceuticals Launches ZERVIATE™ in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5CX3MwNE44QVJIUUlsWGVtb2ZnWnhkOUNNeGpsY1FqT2szdmNqWElfZlhGa1owTVhOb3ZYanFLeUd3SlMyLU9xeDFuYzJobFVscV9vcE9xYlZhY0VObkx2anBDUFR5YlR5OHRvaFk4YXVhdXBWa09kRGd3?oc=5","date":"2018-08-29","type":"pipeline","source":"Modern Retina","summary":"Progression to surgery for ERMs with good vision - Modern Retina","headline":"Progression to surgery for ERMs with good vision","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}